Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Non-cash Items (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Non-cash Items for 6 consecutive years, with $29.6 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items fell 91.82% to $29.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.6 million through Dec 2025, down 91.82% year-over-year, with the annual reading at $29.6 million for FY2025, 91.82% down from the prior year.
  • Non-cash Items for Q4 2025 was $29.6 million at Janux Therapeutics, down from $106.8 million in the prior quarter.
  • The five-year high for Non-cash Items was $361.6 million in Q4 2024, with the low at $5.1 million in Q3 2021.
  • Average Non-cash Items over 5 years is $46.2 million, with a median of $24.1 million recorded in 2023.
  • The sharpest move saw Non-cash Items skyrocketed 2060.97% in 2024, then plummeted 91.82% in 2025.
  • Over 5 years, Non-cash Items stood at $63.0 million in 2021, then crashed by 52.65% to $29.8 million in 2022, then crashed by 43.86% to $16.7 million in 2023, then surged by 2060.97% to $361.6 million in 2024, then tumbled by 91.82% to $29.6 million in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $29.6 million, $106.8 million, and $98.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.